News about Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Pioneers Hope for Rare Genetic Disorders Positive Interim Results in Netherton Syndrome Clini...
Dec 28 2024
ASHBURN, Va. December 18, 2024 In a groundbreaking development for the treatment of rare genetic diseases, Quoin Pharmaceuticals Ltd. (NASDAQ: QN...

QRX003 Innovation Targeting Aberrant Protease Activity in Netherton Syndrome for Breakthrough Treatment,
Dec 19 2024
QRX003: A Promising New Approach in the Management of Netherton Syndrome Quoin Pharmaceuticals Ltd., a company distinguished by its commitment to addr...

Quoin Pharmaceuticals Ltd Prepares for Strategic Insights Ahead of Q3 2024 Financial Performance
Nov 10 2024
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX): Navigating Fiscal Challenges While Pioneering Treatments for Rare Diseases Quoin Pharmaceuticals Ltd. (NAS...

Quoin Pharmaceuticals Advances Clinical Trials for QRX003 A Promising Step Forward in the Fight Against Netherton Syn...
Nov 05 2024
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a noteworthy player in the realm of clinical-stage specialty pharmaceuticals, has made significant strides ...

Quoin Pharmaceuticals Co-Founders Lead by Example with Insider Share Purchases, Reflecting Confidence and Commitment,
Sep 09 2024
Quoin Pharmaceuticals Announces Insider Share Purchases, Signaling Leadership Confidence and Commitment to CompanyFacts:- Quoin Pharmaceutic...

Quoin Pharmaceuticals Set to Pioneer Clinical Pathways for Peeling Skin Syndrome A Hopeful Undertaking for a Rare D...
Aug 06 2024
Abstract Peeling Skin Syndrome (PSS) represents a rare group of autosomal diseases characterized by the shedding of the outermost layer of skin, leadi...

Empowering Ichthyosis Community Quoin Pharmaceuticals Sponsors FIRST 2024 National Conference
Jun 25 2024
ASHBURN, Va., June 25, 2024 In a significant move underscoring its commitment to the rare disease community, Quoin Pharmaceuticals Ltd. (NASDAQ: QNR...

Quoin Pharmaceuticals and University College Cork Collaborate to Develop Novel Topical Rapamycin Formulations for Rar...
Jun 12 2024
Quoin Pharmaceuticals recently announced the signing of a significant research agreement with University College Cork (UCC) in Ireland. This exciting ...

Examination of Quoin Pharmaceuticals Ltd.*s First Quarter 2024 Performance Reveals Strong Results for QNRXsn
May 11 2024
Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) has recently reported disappointing financial results for the first quarter of 2024, indicating a concerning ...

Quoin Pharmaceuticals Ltd Faces Stock Price Plunge in Fourth Quarter of 2023
Mar 15 2024
Quoin Pharmaceuticals Ltd has recently experienced a significant decline in its stock price. Over the course of the last month, the stock has declined...

Quoin Pharmaceuticals* Public Offering Raises Concerns as Company Records Negative ROI and Trails Behind Industry Peers in Financial Performance.
Mar 05 2024
Quoin Pharmaceuticals Public Offering Raises Concerns about Company s Financial HealthASHBURN, Va., March 05, 2024 - Quoin Pharmaceuticals Ltd...

FDA Approves Quoin Pharmaceuticals* Expansion of Netherton Syndrome Clinical Trials to Include Teenage Patients, Promising Expedited Recruitment and Enhanced Data Analysis
Mar 04 2024
FDA Grants Quoin Pharmaceuticals Clearance to Include Teen Patients in Ongoing Netherton Syndrome Clinical Trials: Potentially Expediting Recruitment ...

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
Dec 13 2023
...

Quoin Pharmaceuticals Ltd Faces Intensified Deficit in First Quarter of 2023, with Substantial Losses Reported
May 11 2023
Quoin Pharmaceuticals Ltd, a company operating in the Healthcare sector, recently reported its financial first-quarter results for 2023, which showed ...